261 related articles for article (PubMed ID: 24002093)
1. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Havens PL; Kiser JJ; Stephensen CB; Hazra R; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Gordon CM; Mulligan K;
Antimicrob Agents Chemother; 2013 Nov; 57(11):5619-28. PubMed ID: 24002093
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Havens PL; Hazra R; Stephensen CB; Kiser JJ; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Gordon CM; Mulligan K;
Antivir Ther; 2014; 19(6):613-8. PubMed ID: 24535626
[TBL] [Abstract][Full Text] [Related]
3. Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretroviral therapy.
Bech A; Van Bentum P; Telting D; Gisolf J; Richter C; De Boer H
HIV Clin Trials; 2012; 13(6):350-6. PubMed ID: 23195673
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Havens PL; Long D; Schuster GU; Gordon CM; Price G; Wilson CM; Kapogiannis BG; Mulligan K; Stephensen CB;
Antivir Ther; 2018; 23(7):623-628. PubMed ID: 30260797
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Havens PL; Stephensen CB; Hazra R; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2012 Apr; 54(7):1013-25. PubMed ID: 22267714
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.
Saeedi R; Jiang SY; Holmes DT; Kendler DL
Calcif Tissue Int; 2014 Jun; 94(6):665-8. PubMed ID: 24706031
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
10. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
11. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Duwal S; Schütte C; von Kleist M
PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
[TBL] [Abstract][Full Text] [Related]
13. Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.
Childs KE; Fishman SL; Constable C; Gutierrez JA; Wyatt CM; Dieterich DT; Mullen MP; Branch AD
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):855-9. PubMed ID: 20672993
[TBL] [Abstract][Full Text] [Related]
14. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
[TBL] [Abstract][Full Text] [Related]
15. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.
Masiá M; Padilla S; Robledano C; López N; Ramos JM; Gutiérrez F
AIDS Res Hum Retroviruses; 2012 Mar; 28(3):242-6. PubMed ID: 21639815
[TBL] [Abstract][Full Text] [Related]
16. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
[TBL] [Abstract][Full Text] [Related]
17. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
[TBL] [Abstract][Full Text] [Related]
18. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Day SL; Leake Date HA; Bannister A; Hankins M; Fisher M
J Acquir Immune Defic Syndr; 2005 Mar; 38(3):301-4. PubMed ID: 15735448
[TBL] [Abstract][Full Text] [Related]
19. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
Mashingaidze-Mano R; Bwakura-Dangarembizi MF; Maponga CC; Morse GD; Monera-Penduka TG; Mtisi TJ; Mudzviti T; Mujuru HA
PLoS One; 2020; 15(7):e0235759. PubMed ID: 32634168
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
